Proteomics International is a medical technology company that specialises in proteomics, or the industrial-scale study of the structure and functions of proteins. Proteomics International operates from the Harry Perkins Institute of Medical Research, and is recognised as a world leader in the field of proteomics. Proteomics specialises in predictive diagnostics and bio-analytics services.
Proteomics International aims to develop and commercialise diagnostic tests for chronic disease where there is unmet medical need. Across three divisions – analytical services, diagnostics and therapeutics – Proteomics provides a range of services on a fee-for-service basis, including:
- Pharmacokinetic Testing
- Biosimilars/Biologics Drug Characterisation
- Proteome Mapping
- Protein Quantitation
- Targeted Mass Spectrometry
- Protein ID by Mass Spectrometry
- Post-translational Modifications (PTMs)
Proteomics International was established in 2001, with almost two decades of experience in providing specialised analytical services built around proteomics-based technology. In addition to the Perkins, Proteomics International provides services to groups throughout the Indo-Asian region, with offices in India, Japan, Singapore, Malaysia and Hong Kong.